Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients

<div>The Kaplan-Meier curves for PSA progression-free survival outcome for all Enza-treated CRPC patients with different expression patterns of CXCR7 (P: CXCR7- vs. CXCR7+; P1: CXCR7/1+ vs. CXCR7/2+; P2: CXCR7/2+ vs. CXCR7/3+; P3: CXCR7/1+ vs. CXCR7/3+).</div>

Disease Markers

fig3

Figure 3

Figure 3: Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients 